← All trials
NCT02145377
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2014
- Primary completion
- Mar 1, 2015
- Completion date
- Mar 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- University of MarylandLead sponsor
- University of MarylandOverall official - principal investigator
- University of MarylandReponsible party - principal investigator
- PaxVax, Inc.Collaborator
- Shantha Biotechnics LimitedCollaborator
- Centre pour le developpement des vaccines, MaliOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.